Impact News +++ SAP Aktie mit Kaufsignal: Zahlen und ein erhöhter Ausblick für 2021 (4investors) +++ SAP Aktie +3,07%

FIBROGEN Aktie

 >FIBROGEN Aktienkurs 
16.33 EUR    -1.1%    (Tradegate)
Ask: 16.33 EUR / 197 Stück
Bid: 16.04 EUR / 200 Stück
Tagesumsatz: 77 Stück
Realtime Kurs von 8 bis 22 Uhr!
>FIBROGEN Performance
1 Woche: -45,2%
1 Monat: -42,9%
3 Monate: -49,9%
6 Monate: -60,5%
1 Jahr: -50,5%
laufendes Jahr: -46,9%
>FIBROGEN Aktie
Name:  FIBROGEN INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US31572Q8087 / A12EZ0
Symbol/ Ticker:  1FG (Frankfurt) / FGEN (NASDAQ)
Kürzel:  FRA:1FG, 1FG.F, 1FG:GR, NASDAQ:FGEN
Index:  -
Webseite:  https://www.fibrogen.com/
Marktkapitalisierung:  1470 Mio. EUR
Umsatz:  148.17 Mio. EUR
EBITDA:  -142.71 Mio. EUR
Gewinn je Aktie:  -1.487 EUR
Schulden:  50.08 Mio. EUR
Liquide Mittel:  576.92 Mio. EUR
Umsatz-/ Gewinnwachstum:  715.1% / -
KGV/ KGV lG:  - / -8.89
KUV/ KBV/ PEG:  8.32 / 3.46 / -
Gewinnm./ Eigenkapitalr.:  -107.36% / -38.75%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  FIBROGEN
Letzte Datenerhebung:  14.04.21
>FIBROGEN Eigentümer
Aktien: 91.56 Mio. St.
f.h. Aktien: 84.97 Mio. St.
Insider Eigner: 8.03%
Instit. Eigner: 79.97%
Leerverk. Aktien: 10.92%
>FIBROGEN Peer Group

 
14.04.21 - 03:14
BREAKING NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline - FGEN (PR Newswire)
 
NEW YORK, April 13, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between November 8, 2019 and Ap...
13.04.21 - 22:32
FIBROGEN INC: 8-K Report (SEC Filing)
 
8-K...
13.04.21 - 21:22
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm (PR Newswire)
 
NEW YORK, April 13, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its o...
13.04.21 - 15:51
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA′s Fast Track Tag (Zacks)
 
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up....
12.04.21 - 18:39
FibroGen wins FDA’s fast track designation for experimental DMD therapy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.04.21 - 20:02
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (PR Newswire)
 
LOS ANGELES, April 9, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violati...
07.04.21 - 19:00
Mid-Day Market Update: Crude Oil Down Over 1%; FibroGen Shares Plummet (Benzinga)
 
Midway through trading Wednesday, the Dow traded up 0.02% to 33,437.41 while the NASDAQ rose 0.23% to 13,729.29. The S&P also rose, gaining 0.16% to 4,080.61. read more...
07.04.21 - 17:12
Why FibroGen Stock Is Crashing Today (Fool)
 
The company disclosed a bombshell related to its safety results for lead candidate roxadustat....
07.04.21 - 17:03
Odonate Therapeutics, Ocugen leads healthcare gainers; FibroGen, Homology Medicines among major losers (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.04.21 - 15:57
Why FibroGen′s Stock is Down During Today′s Session (Benzinga)
 
FibroGen's Stock Price And Volume Action FibroGen's (NASDAQ:FGEN) stock has been falling Wednesday, down 35.34% to a price of $22.25. The stock's volume is currently 2.35 million, which is roughly 176.48% of its recent 30-day volume average of 1....
07.04.21 - 15:26
FibroGen Tumbles on Kidney Disease Treatment Data Clarification (The Street)
 
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...
07.04.21 - 15:10
FibroGen Stock Falls Following Disclosure of a "Major 'Oops'" (MarketWatch)
 
The biotech FibroGen revealed a problem with how it had presented safety data for roxadustat, for which it is seeking approval to treat anemia in chronic kidney disease....
07.04.21 - 14:54
Fibrogen hurt by downgrades, Emergent earns a bull despite vaccine mix-up and more in today’s analyst action (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.04.21 - 14:44
FIBROGEN INC: 8-K Report (SEC Filing)
 
8-K...
07.04.21 - 14:18
Upstart Holdings, FibroGen among premarket losers′ pack (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.04.21 - 14:12
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award (Benzinga)
 
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) read more...
07.04.21 - 08:45
FDA AdCom to review FibroGen′s roxadustat application on July 15 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.04.21 - 01:54
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021 (GlobeNewswire EN)
 
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Co...
06.04.21 - 23:02
FIBROGEN INC: 8-K Report (SEC Filing)
 
8-K...
>Zitat des Tages: Urteilskraft ist nicht bei jeder Gelegenheit erforderlich, Takt aber immer. - Philip Dormer Stanhope
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!